PGEN

BEARISH

$3.95 Live

Precigen, Inc. · NASDAQ

Target $9.5 (+140.5%)

$1.23 52W Range $5.47

PGEN Precigen, Inc. - Fundamental Analysis

BEARISH

Console Chart News

PGEN Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$3.95

Analyst Target

$9.5

+140.5% Upside

52W High

$5.47

52W Low

$1.23

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026

Market cap

$1.4B

P/E

N/A

ROE

-572.0%

Profit margin

N/A

Debt/Equity

4.7

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

90%

PGEN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company shows hyper-growth in revenue (283.60% YoY), this is decoupled from profitability, as evidenced by a catastrophic ROE of -571.97% and an operating margin of -474.61%. Valuation metrics are extreme, with a Price/Book ratio of 66.95 and Price/Sales of 144.36, suggesting the stock is trading on pure speculation rather than intrinsic value. The bearish insider sentiment, characterized by a $15.75M sale, further undermines the bullish analyst price targets.

Key Strengths

Exceptional YoY revenue growth of 283.60%

Strong short-term liquidity with a Current Ratio of 3.09

Significant 1-year price appreciation (+188.3%)

Positive analyst target price of $9.50

Recent Q/Q EPS growth improvement (+99.1%)

Key Risks

Extreme fundamental weakness (Piotroski F-Score 1/9)

Severe overvaluation relative to assets (P/B 66.95) and sales (P/S 144.36)

High leverage with a Debt/Equity ratio of 4.70

Consistent history of negative earnings and massive EPS misses

Heavy insider selling ($15.75M in recent transactions)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Bubble

Key drivers: Hyper-growth revenue, Critical financial health failure, Extreme valuation multiples, Bearish insider activity

Confidence

95%

Value

5/100

Stock trades at a massive premium to book value and sales, typical of speculative biotech but extreme even by sector standards.

Positives

No standout positives identified.

Watchpoints

P/B of 66.95 is unsustainable
P/S of 144.36 is extreme
No Graham Number available due to lack of earnings

Future

65/100

Growth is the only bullish driver, but it has yet to translate into a viable path to profitability.

Positives

283.6% Revenue growth
Positive analyst sentiment

Watchpoints

Negative forward P/E
High cash burn implied by operating margins

Past

30/100

Historical performance shows a pattern of volatility and failure to meet earnings expectations.

Positives

Strong 1Y and 3Y price returns

Watchpoints

5Y change is -46.5%
Consistent earnings misses over 25 quarters

Health

10/100

The Piotroski score indicates the company is in the weakest possible health category.

Positives

Current Ratio > 3.0

Watchpoints

Piotroski F-Score 1/9
Debt/Equity 4.70
ROE -571.97%

Dividend

0/100

Non-dividend paying growth/speculative stock.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$3.95

Analyst Target

$9.5

Upside/Downside

+140.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PGEN and closest competitors.

Updated 2026-04-16

Company	5Y	3Y	1Y	6M	1M	1W
PGEN Precigen, Inc. Primary	-46.5%	+240.5%	+188.3%	+13.2%	+11.6%	-7.5%
IMTX Immatics N.V. Peer	-10.0%	+69.3%	+162.7%	+0.7%	+4.0%	+0.8%
NVCR NovoCure Limited Peer	-93.7%	-81.1%	-26.1%	-14.2%	-1.7%	+12.8%
NVAX Novavax, Inc. Peer	-96.2%	-8.1%	+36.0%	-2.5%	-13.8%	+3.2%
ARDX Ardelyx, Inc. Peer	-17.1%	+46.3%	+6.6%	-12.6%	-20.4%	-6.6%

PGE

Precigen, Inc.

Primary

-46.5%

+240.5%

+188.3%

+13.2%

+11.6%

-7.5%

IMT

Immatics N.V.

Peer

-10.0%

+69.3%

+162.7%

+0.7%

+4.0%

+0.8%

NVC

NovoCure Limited

Peer

-93.7%

-81.1%

-26.1%

-14.2%

-1.7%

+12.8%

NVA

Novavax, Inc.

Peer

-96.2%

-8.1%

+36.0%

-2.5%

-13.8%

+3.2%

ARD

Ardelyx, Inc.

Peer

-17.1%

+46.3%

+6.6%

-12.6%

-20.4%

-6.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-17.95

N/A

66.95

144.36

144.41

-13.53

$1.4B

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -474.61%

Gross Margin N/A

ROE -571.97%

ROA -44.3%

Growth

Revenue and earnings growth rates

Revenue Growth +283.6%

Earnings Growth N/A

Q/Q Revenue Growth +283.61%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

4.7

High debt

Current Ratio

3.09

Strong

Quick Ratio

2.74

Excellent

Cash/Share

$0.28

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

65.0%

Op. Margin

-474.6%

Net Margin

-514.9%

Total Assets

$0.2B

Liabilities

$0.1B

Equity

$0.0B

Debt/Equity

6.44x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14

$N/A

2026-03-25

$-0.01

+88.1% surprise

2025-11-13

$-1.06

-1015.8% surprise

2025-08-12

$-0.08

+4.1% surprise

Healthcare Sector Comparison

Comparing PGEN against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)

Return on Equity (ROE)

-571.97%

This Stock

-101.52%

Sector Avg

+463.4% (Excellent)

Debt to Equity

4.7

This Stock

3.4

Sector Avg

+38.2% (Higher)

Revenue Growth

283.6%

This Stock

124.21%

Sector Avg

+128.3% (Fast Growth)

Current Ratio

3.09

This Stock

4.56

Sector Avg

-32.3% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PGEN Precigen, Inc.	BEARISH	$1.4B	-	-572.0%	-%	$3.95
IMTX Immatics N.V.	BEARISH	$1.4B	-	-37.1%	-%	$10.43	Compare
NVCR NovoCure Limited	BEARISH	$1.38B	-	-38.9%	-20.8%	$12.17	Compare
NVAX Novavax, Inc.	NEUTRAL	$1.42B	3.25	-%	39.2%	$8.69	Compare
ARDX Ardelyx, Inc.	NEUTRAL	$1.42B	-	-36.2%	-15.1%	$5.78	Compare

PGEN Precigen, Inc.

BEARISH

Mkt Cap

$1.4B

P/E

ROE

-572.0%

Price

$3.95

Compare with PGEN

NVCR NovoCure Limited

Compare with PGEN

Compare with PGEN

Compare with PGEN

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-30	KIRK RANDAL JOE	Director and Beneficial Owner of more than 10% of a Class of Security	Sale	4,772,781	$15,750,177
2026-03-18	LEHR DONALD P	Officer	Stock Award	40,443	-
2026-03-18	SABZEVARI HELEN	Chief Executive Officer	Stock Award	321,100	-
2026-03-18	THOMASIAN HARRY JR.	Chief Financial Officer	Stock Award	40,293	-
2026-03-18	SHAH RUTUL R.	Chief Operating Officer	Stock Award	44,495	-
2026-03-18	TENNANT PHIL	Officer	Stock Award	42,110	-
2026-03-13	ALVAREZ CESAR LICINIO	Director	Stock Award	71,839	-
2026-03-13	HASSAN FRED	Director	Stock Award	71,839	-
2026-03-13	KINDLER JEFFREY B	Director	Stock Award	71,839	-
2026-03-13	KIRK RANDAL JOE	Director and Beneficial Owner of more than 10% of a Class of Security	Stock Award	143,678	-
2026-03-13	AGEE NANCY HOWELL	Director	Stock Award	71,839	-
2026-03-13	TURLEY JAMES S	Director	Stock Award	71,839	-
2026-03-13	FRANK STEVEN R	Director	Stock Award	71,839	-
2026-03-13	GUPTA VINITA D	Director	Stock Award	71,839	-
2026-03-10	ALVAREZ CESAR LICINIO	Director	Stock Award	17,806	$62,499

KIRK RANDAL JOE

Director and Beneficial Owner of more than 10% of a Class of Security

Sell

2026-03-30

4,772,781 shares · $15,750,177

LEHR DONALD P

Officer

Stock Award

2026-03-18

40,443 shares

SABZEVARI HELEN

Chief Executive Officer

Stock Award

2026-03-18

321,100 shares

THOMASIAN HARRY JR.

Chief Financial Officer

Stock Award

2026-03-18

40,293 shares

SHAH RUTUL R.

Chief Operating Officer

Stock Award

2026-03-18

44,495 shares

TENNANT PHIL

Officer

Stock Award

2026-03-18

42,110 shares

ALVAREZ CESAR LICINIO

Director

Stock Award

2026-03-13

71,839 shares

HASSAN FRED

Director

Stock Award

2026-03-13

71,839 shares

KINDLER JEFFREY B

Director

Stock Award

2026-03-13

71,839 shares

KIRK RANDAL JOE

Director and Beneficial Owner of more than 10% of a Class of Security

Stock Award

2026-03-13

143,678 shares

AGEE NANCY HOWELL

Director

Stock Award

2026-03-13

71,839 shares

TURLEY JAMES S

Director

Stock Award

2026-03-13

71,839 shares

FRANK STEVEN R

Director

Stock Award

2026-03-13

71,839 shares

GUPTA VINITA D

Director

Stock Award

2026-03-13

71,839 shares

ALVAREZ CESAR LICINIO

Director

Stock Award

2026-03-10

17,806 shares · $62,499

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

FORM 8-K

2026-03-25

10-K

2026-03-25

PGEN filed its annual 10-K report on March 25, 2026, which includes detailed disclosures on its business operations and financial condition. The filing provides management's analysis of results of operations and outlines the company's specific risk factors.

8-K

FORM 8-K

2025-11-13

Precigen, Inc. filed a Form 8-K on November 13, 2025, likely to announce its third-quarter financial results.

10-Q

2025-11-13

Precigen (PGEN) filed its 10-Q on November 13, 2025. The filing includes a discussion of the company's risk factors, although specific financial highlights were not provided in the available excerpt.

8-K

FORM 8-K

2025-09-17

8-K

FORM 8-K

2025-09-03

8-K

FORM 8-K

2025-08-18

Precigen, Inc. (PGEN) filed a Form 8-K, likely to announce its second-quarter financial results for 2025.

8-K

FORM 8-K

2025-08-18

Precigen, Inc. (PGEN) filed a Form 8-K, likely to announce its second-quarter financial results for 2025.

10-Q

2025-08-12

Precigen (PGEN) filed its quarterly 10-Q report on August 12, 2025. The provided excerpts do not contain specific financial highlights or detailed risk factors.

8-K

FORM 8-K

2025-06-30

Precigen, Inc. filed an 8-K on June 30, 2025, likely reporting its second-quarter financial results or a material corporate update coinciding with the end of the fiscal quarter.

DEF 14A

2025-05-16

10-Q

2025-05-14

8-K

FORM 8-K

2025-05-14

10-K

2025-03-19

8-K

FORM 8-K

2025-03-19

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

2 analysts

Citizens

2026-03-26

Maintains

Market Outperform Market Outperform

HC Wainwright & Co.

2026-03-26

Maintains

Buy Buy

HC Wainwright & Co.

2025-11-14

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning PGEN from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PGEN

PGEN Precigen, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!